Optimizing meropenem administration in ICU patients
A Pilot Study for Optimizing Meropenem Administration in the Intensive Care Unit - Short Six Times vs Prolonged Three Times Courses Daily
This study tests if giving the antibiotic meropenem in smaller, more frequent doses can work just as well for ICU patients with serious infections as the standard larger doses.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Oslo University Hospital Academic / other |
| Locations | 1 site (Oslo) |
| Trial ID | NCT05578586 on ClinicalTrials.gov |
What this trial studies
This pilot study investigates whether administering the antibiotic meropenem as 1 gram in 15-minute infusions six times daily can achieve similar serum concentrations as the standard 2 grams in 3-hour infusions three times daily. The study focuses on patients in the intensive care unit (ICU) who require intravenous access for treatment of serious infections. By comparing these two dosing regimens, the researchers aim to determine if shorter, more frequent infusions can maintain effective drug levels while potentially increasing the availability of intravenous access. The study will also monitor patient outcomes, including hospital stay duration and 30-day mortality rates.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older admitted to the ICU who require treatment with meropenem for serious infections.
Not a fit: Patients with known hypersensitivity to betalactam antibiotics, those using valproate, pregnant individuals, or those unable to provide consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve antibiotic administration efficiency and patient outcomes in the ICU.
How similar studies have performed: While this approach is novel in the context of meropenem administration, similar studies have explored alternative dosing strategies for antibiotics with varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients ≥ 18 years admitted to the ICU at Oslo University Hospital, Rikshospitalet and 2. who shall be treated with meropenem because of proven or suspected serious infection and 3. who give their written informed consent either directly or through next of kin Exclusion Criteria: Patients 1. with known hypersensistivity to betalactam antibiotics or 2. who use of valproat or 3. who are pregnant or 4. the lack of consent.
Where this trial is running
Oslo
- Oslo University Hospital — Oslo, Norway (Recruiting)
Study contacts
- Principal investigator: Ingvild Nordøy, PhD — Oslo University Hospital
- Study coordinator: Ingvild Nordøy, PhD
- Email: inordoy@ous-hf.no
- Phone: +4793028084
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.